Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats
| Autor: | Burak Dik, Devran Coskun, Emre Bahcivan, Kamil Uney |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Blood Glucose
Male medicine.medical_treatment Lansoprazole Pharmacology Albendazole Benzimidazole Article Diabetes Mellitus Experimental chemistry.chemical_compound Insulin resistance Diabetes mellitus medicine Animals Hypoglycemic Agents Insulin rat Rats Wistar antiabetic Triglycerides Glycated Hemoglobin diabetes Triglyceride business.industry Cholesterol General Medicine medicine.disease Rats Glucose Diabetes Mellitus Type 2 Pharmaceutical Preparations chemistry Homeostatic model assessment HOMA-β Insulin Resistance business medicine.drug |
| Zdroj: | Turkish Journal of Medical Sciences |
| ISSN: | 1303-6165 |
| Popis: | Background/aim The aim of this study is to determine the effects of different concentrations of albendazole and lansoprazole, which were benzimidazole derivatives, on endocrinologic and biochemical parameters in experimental type 2 diabetic (T2D) rats. Materials and methods In this study, 46 male Wistar Albino rats were used. Animals were divided as healthy control (0.1 mL/rat/day saline, s.c, n = 6), diabetes control (0.1 mL/rat/day saline, s.c, n = 8), diabetes+low-dose albendazole (5 mg/kg, oral, n = 8), diabetes+high-dose albendazole (10 mg/kg, oral n = 8), diabetes+low-dose lansoprazole (15 mg/kg, subcutaneous, n = 8), and diabetes+high-dose lansoprazole (30 mg/kg, subcutaneous, n = 8). All groups were treated for 8 weeks. The blood samples were analyzed by autoanalyzer and ELISA kits for biochemical and endocrinological parameters, respectively. Results Glucose, HbA1c, triglyceride, low density cholesterol (LDL), leptin, and Homeostatic Model Assessment for insulin resistance (HOMA-IR) levels increased and insulin and HOMA-β levels decreased in the diabetic rats compared to the healthy control group. The glucose, HbA1c, and triglyceride levels were partially decreased; however, insulin and HOMA-β levels were increased by low-dose albendazole therapy. The high dose of lansoprazole treatment increased insulin level. Conclusion The lansoprazole and albendazole treatments can be a potential drug or combined with antidiabetic drugs in T2D treatment by Adenosine 5 ′ -monophosphate activated protein kinase (AMPK), peroxisome proliferator-activated receptor (PPAR), incretin-like effect and other antidiabetic mechanisms. It may be beneficial to create an effective treatment strategy by developing more specific substances with benzimidazole scaffold. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|